US2017157181A1PendingUtilityA1

Methods of generating, repairing and/or maintaining connective tissue in vivo

58
Assignee: GHOSH PETERPriority: Aug 6, 2007Filed: Jun 9, 2016Published: Jun 8, 2017
Est. expiryAug 6, 2027(~1.1 yrs left)· nominal 20-yr term from priority
Inventors:Peter Ghosh
A61P 43/00A61P 25/00A61P 25/02A61P 29/00A61P 25/04A61K 47/36A61K 2300/00A61K 35/28A61P 19/02A61K 31/726A61P 19/04A61P 1/04A61K 31/728A61K 2035/124A61K 35/545A61K 38/14C12N 5/0663A61P 19/00A61P 21/00A61K 9/4866C12N 2501/905A61K 31/737A61P 17/06A61K 35/12A61P 19/08A61L 2430/38A61L 27/52A61L 27/3856A61L 27/3834A61K 31/727
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention relates to a method for generating, repairing and/or maintaining connective tissue in a subject. In one embodiment, the invention relates to a method for generating, repairing and/or maintaining cartilage tissue in a subject. The present invention also relates to a method of treating and/or preventing a disease in a subject arising from degradation and inflammation of connective tissue.

Claims

exact text as granted — not AI-modified
1 - 15 . (canceled) 
     
     
         16 . A therapeutic composition comprising a population of human cells enriched for STRO-1 bright  mesenchymal precursor cells (MPCs) or culture-expanded multipotent progeny thereof; and chondroprotective agent. 
     
     
         17 . The therapeutic composition of  claim 16 , wherein the chondroprotective agent comprises an chondroprotective agent selected from the group consisting of: pentosan polysulfate, glycosaminoglycan polysufate ester, glyciamino-glycan-peptide complex, and Hyaluronic Acid (HA). 
     
     
         18 . The therapeutic composition of  claim 17 , wherein the chondroprotective agent comprises HA. 
     
     
         19 . The therapeutic composition of  claim 16 , further comprising a cryoprotectant. 
     
     
         20 . The therapeutic composition of  claim 16 , wherein the MPCs carry at least one additional marker selected from the group of surface markers consisting of THY-1, VCAM-1, STRO-2, TNAP, and CD146. 
     
     
         21 . The therapeutic composition of  claim 20 , wherein the MPCs carry the marker TNAP. 
     
     
         22 . The therapeutic composition of  claim 16 , further comprising an in situ-polymerizable gel. 
     
     
         23 . The therapeutic composition of  claim 22 , wherein the in situ-polymerizable gel comprises alginate. 
     
     
         24 . The therapeutic composition of  claim 16 , wherein the population is encapsulated. 
     
     
         25 . The therapeutic composition of  claim 16 , wherein the population is an allogeneic population. 
     
     
         26 . The therapeutic composition of  claim 16 , wherein the population is an autologous population. 
     
     
         27 . The therapeutic composition of  claim 16 , wherein the population is a genetically modified population. 
     
     
         28 . The therapeutic composition of  claim 27 , wherein the cells in the genetically modified population comprise an exogenous polynucleotide that encodes a selective marker, a cytokine, or a chemokine. 
     
     
         29 . The therapeutic composition of  claim 16 , wherein the STRO-1 bright  cells are STRO-1 bright  cells enriched from bone marrow.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.